Huntington's chorea is an autosomal dominant degenerative central nervous disorder producing chorea and dementia. The disorder has been considered the "opposite" motor lesion to Parkinson's disease. The principal neuropathology involves degeneration of the basal ganglia, particularly the caudate nucleus, affecting the small interneurones, Golgi type 2 (Bruyn, 1968) .
The neurochemical changes involve findings in three neurotransmitter systems: amine, gamma aminobutyric acid (GABA), and cholinergic.
Attempts to find reproducible abnormalities of amines, particularly dopamine and 5-hydroxytryptamine (5-HT) have failed (Bernheimer and Hornykiewicz, 1973; Chase, 1973; Bird and Iversen, 1974) . Evidence from drug effects is more suggestive. Dopamine competitive inhibitors, such as haloperidol, and dopamine depleters, such as reserpine and tetrabenazine, improve choreatic movements temporarily, and this suggests that there is relative overactivity of the dopaminergic system.
Decreased levels of GABA and its biosynthetic enzyme, glutamine acid decarboxylase (GAD) have been reported (Bird et al., 1973; Iversen et al., 1974; Urquhart et al., 1975) . Degeneration of the small cholinergic interneurones of the corpus striatum and low levels of choline acetyltransferase have been found in choreatic brains at post-mortem McGeer and McGeer, 1976) .
The human platelet provides a ready source of monoamine oxidase in humans. Alterations in the activity of this intraneuronal enzyme can affect free intracellular amine levels and uptake from the intrasynaptic cleft (Hughes, 1972) . Platelet monoamine oxidase activity may be altered in diseases affecting the central nervous system, for example, Parkinson's disease (Zeller et al., 1976) , migraine (Sicuteri et al., 1972; Glover et al., 1977a) affective disorders (Murphy and Weiss, 1972; Landowski et al., 1975) , and schizophrenia (Wyatt and Murphy, 1976) . These conditions have amine disorders as a common suggested feature.
No studies of platelet monoamine oxidase activity in Huntington's disease have been reported. Platelet monoamine oxidase is a type B monoamine oxidase (Collins and Sandler, 1971) of which dopamine is a substrate (Glover et al., 1977b) . Its activity is under significant genetic control (Nies et al., 1974) . Increased dopamine uptake has been found in human platelets in Huntington's chorea (Aminoff et al., 1974; McLean and Nihei, 1977) .
As Huntington's chorea is determined genetically and aminergic neurone dysfunction is suggested as part of the pathology, a study of platelet monoamine oxidase activity in this disorder seemed indicated.
Patients and methods
Since 1972, a Huntington's chorea clinic has been conducted in the Department of Psychiatry, University of Melbourne. Fifteen consecutive patients attending the clinic, and on medication, were used in this study. The diagnosis was established by the clinical picture, the evolution of the disease under observation, and the family history.
A global assessment was made of the patients' condition by EC at the time of blood sampling. The samples were assayed by JM who was unaware of the clinical assessment. Each patient was sampled on two occasions but some samples were discarded because of contamination of the platelet plug with red cells. On the second run samples, patients were coded differently and the order changed.
A group of normal control subjects was drawn from members of staff who were drug-free, without physical and psychiatric disorders, and had no family history of neurological or psychiatric disorders. These were assayed in the same batches as the patients.
The method of sampling and assay is detailed elsewhere (Mann, 1977) . Ten millilitres of blood was withdrawn into a plastic tube containing EDTA and immediately transferred to the laboratory. At 40C a platelet plug was separated by differential centrifugation, washed in 5 ml of normal saline and suspended in 1 ml of normal saline. Storage at -200C preserved monoamine oxidase activity for at least three weeks. The radiochemical assay was modified from Jarrott (1974) ; 50 pl of platelet suspension was incubated at 300C with 20,u1 of 14C-benzylamine (2 mmol, l1xCi/,4l) or 14C-tyramine (2 mmol, l,Ci/t,l) and 30 ,ul of distilled water. Blanks had 10 ,ul of 3 M HCl (used to stop the reaction) added just before the substrate. Products were extracted into butylacetate and counted in a Packard Tricarb liquid scintillation spectrometer. Reaction rates were linear with respect to incubation time and enzyme concentration.
All samples were assayed in triplicate with the two substrates. All runs included internal blanks for increased reliability. The coefficient of variance (CV) for a single sample assayed 10 times in one batch was 1. 1% and the interbatch CV was 5%.
Protein concentration was estimated according to the method of Lowry et al. (1951) .
Results
The clinical and biochemical details are shown in Table 1 for the experimental group.
Results for the control group studied are shown in Table 2 .
In the control group, females had higher mean platelet monoamine oxidase activity than males (P<0.01). This created the need for same sex contrasts in establishing real differences in monoamine oxidase activity. The normal control group showed no significant correlation between age and platelet monoamine oxidase activity with either substrate (P>0.05). Both whole group and same sex contrasts were made of mean platelet monoamine oxidase activity as measured by the two substrates. A twotailed t test indicated that the experimental group as a whole had a significantly higher mean platelet monoamine oxidase activity than normal controls using benzylamine as a substrate (P=0.04). Same sex contrasts showed this was true only for male Huntington's chorea patients. This group had higher monoamine oxidase activity than male controls with benzylamine (P=0.036) and tyramine (P=0.057).
The two patients (numbers 9 and 15) whose treatment response was assessed as excellent had the lowest monoamine oxidase activity. Both had almost identical activity (nmol/mg/hr), respectively 20.9 and 20.4 for benzylamine and 18.7 and 17.0 for tyramine. No other patient had a monoamine oxidase activity below 30 nmol/mg/hr with benzylamine. Similar results were obtained with these two patients on the second sampling.
At the second sampling, two patients had improved significantly clinically (numbers 3 and 8). Patient 8 had had haloperidol 6 mg daily added to his treatment. Both these patients showed a significant fall in platelet monoamine oxidase activity. Patient 3 had gone from 53.5 to 21.0 (benzylamine) and 46.0 to 17.8 (tyramine), and patient 8 from 34.1 to 21.2 (tyramine). These values were comparable to the patients rated as excellent.
Four patients had deteriorated and there was no consistent significant change in monoamine oxidase activity. A change of greater than 17% was considered significant, as this was the variance in controls over one month.
A paired t test applied to the whole Huntington's group failed to show any significant difference between the first and second samples (P>0.70 for benzylamine, P>0.60 for tyramine).
Discussion
Significantly higher platelet monoamine oxidase activity was found in male Huntington's patients compared with control subjects. Although mean female platelet monoamine oxidase values were higher than normal female control subjects, they were not significantly different. There are no other reports in the literature of studies of platelet monoamine oxidase activity in this condition with which to contrast these results. Low monoamine oxidase activity has been reported in Parkinson's disease (Zeller et al., 1976) .
Markedly (Wyatt and Murphy, 1976) . Lithium carbonate has been demonstrated to raise monoamine oxidase activity (Bockar et al., 1974 
